#151156

Anti-Rb1 [Rb1 (1F8)]

Cat. #151156

Anti-Rb1 [Rb1 (1F8)]

Cat. #: 151156

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 1-2 weeks

Target: Retinoblastoma (Rb1)

Class: Monoclonal

Application: IHC ; IF ; IP

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: David Lane

Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-Rb1 [Rb1 (1F8)]
  • Alternate name: CD4 Molecule; T-Cell Surface Antigen T4/Leu-3; T-Cell Surface Glycoprotein CD4; CD4 Receptor; CD4 Antigen
  • Clone: Rb1 (1F8)
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Molecular weight: 105 kDa
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Disease: Breast Cancer
  • Application: IHC ; IF ; IP
  • Description: The Retinoblastoma protein (Rb) is a transcription factor that controls cell cycle progression (at the G1/S phase transition) through its repression of E2F-mediated transcription. Mutation of the Rb gene is found frequently in human sarcomas, lung, bladder and breast carcinomas and is the molecular basis for hereditary disposition to retinoblastoma.
  • Immunogen: Rb-b-galactosidase fusion protein spanning nucleotides 1126-1973 and representing 283 mino acids of Human Rb cDNA
  • Isotype: IgG1
  • Myeloma used: Sp2/0-Ag14

Target Details

  • Target: Retinoblastoma (Rb1)
  • Molecular weight: 105 kDa
  • Target background: The Retinoblastoma protein (Rb) is a transcription factor that controls cell cycle progression (at the G1/S phase transition) through its repression of E2F-mediated transcription. Mutation of the Rb gene is found frequently in human sarcomas, lung, bladder and breast carcinomas and is the molecular basis for hereditary disposition to retinoblastoma.

Applications

  • Application: IHC ; IF ; IP

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates.
  • Ragazzon et al. 2014. Eur J Endocrinol. 2014 Feb 4
  • 170(3):385-91. PMID: 24347427
  • Bandyopadhyay et al. 2007. Aging Cell. 6(4):577-91. PMID: 17578512.
  • Dynamic assembly of chromatin complexes during cellular senescence: implications for the growth arrest of human melanocytic nevi.
  • Lee et al. 2007. Clin Cancer Res. 13(3):832-8. PMID: 17289874.
  • Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer.
  • Bartkova et al. 2003. J Pathol. 200(2):149-56. PMID: 12754735.
  • Deregulation of the RB pathway in human testicular germ cell tumours.
  • Brtek et al. 1992. Oncogene. 7(1):101-8. PMID: 1741157.
  • Cellular localization and T antigen binding of the retinoblastoma protein.
  • Grand et al. 1989. Oncogene. 4(11):1291-8. PMID: 2682458.
  • The expression of the retinoblastoma gene product Rb1 in primary and adenovirus-transformed human cells.